Nicola Schiano Moriello

Assistant professor

University of Naples Federico II

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Nicola Schiano Moriello is an Assistant Professor at the University of Naples Federico II in Italy. His research focuses on infectious diseases, particularly COVID-19, and the treatment of resistant bacterial infections. Recent articles authored by Dr. Moriello include studies on the efficacy of antiviral therapies and personalized care approaches to hepatitis C, showcasing his commitment to advancing clinical practices in these critical areas.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (4)

Riccardo Scotto

University of Naples Federico II

ITALY

View details

Ivan Gentile

University of Naples Federico II

ITALY

View details

Daniele Roberto Giacobbe

University of Genoa

ITALY

View details

Hasse Melbye

Professor

UiT Norges arktiske universitet

NORWAY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nicola Schiano Moriello

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

COVID-19 in immunocompromised patients: proposed definition of a new entity with prolonged infection

Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)

Personalized care approaches to hepatitis C therapy: recent advances and future directions

Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study

The Role of CRP POC Testing in the Fight against Antibiotic Overuse in European Primary Care: Recommendations from a European Expert Panel

Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19

CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy

Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience

Microbiota and hepatitis C virus in the era of direct-acting antiviral agents

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Collaborators (4)

Riccardo Scotto

Ivan Gentile

Daniele Roberto Giacobbe

Hasse Melbye

Make your next move.